Related Experiment Video
Updated: Jan 21, 2026
10:08
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
13.9K
Noncoding RNAs in exercise-induced cardio-protection for chronic heart failure
1Department of Cardiology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Ebiomedicine
|July 29, 2019
Summary
Exercise benefits chronic heart failure (CHF) through exercise-induced cardioprotection (EIC), but mechanisms remain unclear. This review explores noncoding RNAs (ncRNAs) in EIC for CHF, assessing their therapeutic potential and limitations.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Chronic heart failure (CHF) presents a significant global health burden due to high morbidity and mortality.
- Exercise-induced cardioprotection (EIC) shows promise for CHF management, yet its mechanisms and clinical utility are debated.
- Noncoding RNAs (ncRNAs) are emerging as critical regulators in cardiovascular disease and potential therapeutic targets for CHF.
Purpose of the Study:
- To review the current understanding of ncRNAs' roles in EIC for CHF.
- To evaluate the prospective applications and limitations of ncRNAs in clinical settings for CHF.
Main Methods:
- Literature review of studies investigating ncRNAs in exercise-induced cardioprotection for chronic heart failure.
- Analysis of current research on the mechanisms and clinical relevance of ncRNAs in EIC and CHF.
Main Results:
- Numerous ncRNAs have been identified as key players in both EIC and the pathophysiology of CHF.
- Evidence suggests specific ncRNAs mediate beneficial effects of exercise in heart failure models.
- The precise molecular pathways and clinical translatability of these ncRNAs require further elucidation.
Conclusions:
- ncRNAs represent promising therapeutic targets for enhancing EIC in CHF.
- Further research is needed to overcome challenges in clinical application and fully harness the potential of ncRNAs for CHF treatment.
- Understanding ncRNA mechanisms in EIC is crucial for developing novel therapeutic strategies for chronic heart failure.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
783
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
783
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
723
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
723
01:22Heart Failure VI: Adjunct Therapies
277
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
277
01:22Heart Failure Drugs: Diuretics
824
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
824
01:30Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227